NCT01376713View on ClinicalTrials.gov

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

May 31, 2015

Conditions
Stage III MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

Ofatumumab

Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks

BIOLOGICAL

Ofatumumab plus Dacarbazine

"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."

Trial Locations (2)

1030

Rudolfstiftung, Vienna

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01376713 - Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | Biotech Hunter | Biotech Hunter